Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.58 |
| ▸ | HPGD | P15428 | 5/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | ATM | Q13315 | 3/20 | 0.58 |
| ▸ | GLA | P06280 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | CASP1 | P29466 | 1/20 | 0.58 |
| ▸ | CASP7 | P55210 | 1/20 | 0.58 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.53 |
| ▸ | XDH | P47989 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2889004 | 0.91 | ALDH1A1 (0.53) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL4914225 | 0.89 | KDM4E (0.46) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL9617019 | 0.89 | NOTUM (0.53) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL15878431 | 0.89 | NOTUM (0.53) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL31521444 | 0.89 | NOTUM (0.53) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL70233 | 0.85 | KDM4E (0.62) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL14797167 | 0.84 | ALDH1A1 (0.46) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL203438 | 0.84 | GSK3B (0.49) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL27437528 | 0.84 | KDM4E (0.46) | KDM4EALDH1A1HSD17B10HPGDMAPT | |
| SCHEMBL12151586 | 0.84 | NOTUM (0.64) | KDM4EALDH1A1HSD17B10HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4210687-A | — | — | None | — | — | JP | disclosed |
| WO-2025045826-A1 | COMPOUNDS FOR ACTIVATION OF FGFR1 SIGNALING | THE CULTIVATED B. GMBH (DE) | 2025-03-06 | — | — | WO | disclosed |
| US-11964988-B2 | Fused heterocyclic compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2024-04-23 | — | — | US | disclosed |
| EP-3240572-B1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-01 | — | — | EP | disclosed |
| WO-2023186881-A1 | P38 MAP KINASE INHIBITORS FOR USE IN THE TREATMENT OF COLORECTAL CANCER | BADEN-WÜRTTEMBERG STIFTUNG GGMBH (DE) | 2023-10-05 | — | — | WO | disclosed |
| EP-3849986-B1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2022-06-08 | — | — | EP | disclosed |
| US-20220112214-A1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2022-04-14 | — | — | US | disclosed |
| EP-3849986-A1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2021-07-21 | — | — | EP | disclosed |
| CN-112996794-A | Fused heterocyclic compounds as RET kinase inhibitors | 阿雷生物药品公司 | 2021-06-18 | — | — | CN | disclosed |
| EP-3240546-B1 | TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2020-10-21 | — | — | EP | disclosed |
| US-4104280-A | Dibenzo [b.f]thiepin and dibenzo[b.f]oxepin derivatives | SYNTEX (U.S.A.) INC. (US) | 1978-08-01 | — | — | US | disclosed |
| US-3989721-A | Disubstituted xanthone carboxylic acid compounds | SYNTEX (U.S.A.) INC. (US) | 1976-11-02 | — | — | US | disclosed |
| US-3989720-A | Disubstituted xanthone carboxylic acid compounds | SYNTEX (U.S.A.) INC. (US) | 1976-11-02 | — | — | US | disclosed |
| US-3988352-A | Disubstituted xanthone carboxylic acid compounds | SYNTEX (U.S.A.) INC. (US) | 1976-10-26 | — | — | US | disclosed |
| US-3979414-A | Disubstituted xanthone carboxylic acid compounds | SYNTEX (U.S.A.) INC. (US) | 1976-09-07 | — | — | US | disclosed |
| US-3965115-A | Disubstituted xanthone carboxylic acid compounds | SYNTEX (U.S.A.) INC. (US) | 1976-06-22 | — | — | US | disclosed |
| US-3963753-A | Disubstituted xanthone carboxylic acid compounds | SYNTEX (U.S.A.) INC. (US) | 1976-06-15 | — | — | US | disclosed |
| US-3963752-A | Disubstituted xanthone carboxylic acid compounds | SYNTEX (U.S.A.) INC. (US) | 1976-06-15 | — | — | US | disclosed |
| US-3951618-A | Method of use of, and compositions containing, disubstituted xanthone carboxylic acid compounds | SYNTEX (U.S.A.) INC. (US) | 1976-04-20 | — | — | US | disclosed |
| US-3949084-A | Novel substituted xanthone carboxylic acid compounds | SYNTEX (U.S.A.) INC. (US) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112214-A1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, FRK | KDM4E 1311/4885ALDH1A1 3607/4885HSD17B10 3694/4885 |
| US-11964988-B2 | Fused heterocyclic compounds as RET kinase inhibitors | RET, ROR1, FRK | KDM4E 1311/4885ALDH1A1 3607/4885HSD17B10 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.